ENDV (Endonovo Therapeutics) Other Current Liabilities: $6.34 Mil (As of Jun. 2025)


What is Endonovo Therapeutics Other Current Liabilities?

Endonovo Therapeutics ENDV -99.00% Other Current Liabilities is $6.34 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Endonovo Therapeutics's other current liabilities for the quarter that ended in Jun. 2025 was $6.34 Mil.

Endonovo Therapeutics's quarterly other current liabilities increased from Dec. 2024 ($6.34 Mil) to Mar. 2025 ($6.34 Mil) but then from Mar. 2025 ($6.34 Mil) to Jun. 2025 ($6.34 Mil).

Endonovo Therapeutics's annual other current liabilities declined from Dec. 2022 ($17.36 Mil) to Dec. 2023 ($6.34 Mil) but then stayed the same from Dec. 2023 ($6.34 Mil) to Dec. 2024 ($6.34 Mil).

Endonovo Therapeutics Other Current Liabilities Related Terms

Endonovo Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics Other Current Liabilities Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.20 3.44 17.36 6.34 6.34

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.34 6.34 6.34 6.34 6.34

Endonovo Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $6.34 Mil mean?
Endonovo Therapeutics (ENDV) has a Other Current Liabilities of $6.34 Mil as of Jun. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Endonovo Therapeutics.
Is Endonovo Therapeutics' Other Current Liabilities too high?
Endonovo Therapeutics' current Other Current Liabilities is $6.34 Mil.
How does Endonovo Therapeutics' Other Current Liabilities compare to RGBP and SIGY?
Endonovo Therapeutics' Other Current Liabilities of $6.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Endonovo Therapeutics. Endonovo Therapeutics's current Other Current Liabilities is $6.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Other Current Liabilities of $6.34 Mil. The current Other Current Liabilities is $6.34 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Other Current Liabilities is $6.34 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.